To my knowledge, VIR’s is the only HBV program planning to incorporate peg-IFN (in the phase-2 trial). Fans of JNJ/ARWR's program claim VIR's use of peg-IFN is a sign of weakness. Do you concur?
Thanks for posting the terms of the VIR-ANLY collaboration.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”